BOSTON (TheStreet) -- Please join me at 12 p.m. ET today for the next Biotech Stock Mailbag Live Chat.
I'll answer your questions and respond to your comments in what I hope will be an informative and fun discussion about the current state of the biotech investment sector. A sign-up link to the live chat is below.
Before I get to your questions, I want to update this week's column on noteworthy biotech stock trades in the second half of 2011. Of course, I forgot to include a couple of stocks.First, Pacira Pharmaceuticals (PCRX) is expecting an FDA approval decision on Oct. 28 for Exparel in post-surgical pain management. Exparel is a proprietary, long-acting formulation of the painkiller bupivacaine. FDA extended the Exparel review by three months because Pacira submitted additional information. I met with Pacira executives a couple of weeks ago and walked out confident in Exparel's approval. The three-month delay sounded much more procedural than anything worrisome. Second, I failed to include the expected results from a phase III study of Biodelivery Sciences' (BDSI) BEMA buprenorphine in the third quarter. BEMA buprenorphine is a thin, dissolvable film placed inside the cheek that contains the painkiller buprenorphine. To your questions: Paul K. asks, "What the [bleep] is going on with Adventrx Pharmaceuticals (ANX)? The stock goes up every day." Let's do some calculations to illustrate why Adventrx is overvalued (perhaps wildly so) on a fundamental basis. [Yes, I know, the stock is a trader's chew toy at the moment, and fundamentals don't matter, but at some point, they will.] First, I'm going to assume that exelbine, Adventrx's reformulation of the lung cancer drug vinorelbine, is approved on Sept. 1. I won't even risk-adjust for the possibility of a rejection. I'll also assume that Adventrx retains 100% of exelbine's sales -- that means no partner, no shared revenue. With exelbine ready for launch, let's figure out the commercial opportunity. A logical place to start, of course, would be U.S. sales of vinorelbine since Adventrx's marketing strategy will be to convince doctors to switch from vinorelbine to exelbine. Here's where the story gets dicey for Adventrx: U.S. sales of vinorelbine totaled $7 million over the past 12 months (June 2010 through May 2011), according to IMS Health. For calendar year 2010, vinorelbine sales totaled $7.6 million, according to IMS Health.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV